•  
  •  
  •  
  •  

2026-08-08 23:00:39

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  DrReddysLaboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar
  • Dr. Reddy's Laboratories Reports Q1 FY27 Results: Net Profit Stands at ₹435 Crore Amid North America Softness; Sequential Earnings Surge 97%
  • Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States
  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 8
  • Dr. Reddys Laboratories Ltd consolidated Q4 FY2025-26 PAT slides to Rs. 220.1 crores
  • Dr. Reddy's and Nestlé Health Science strengthens presence in diabetes & obesity nutrition space with Celevida® GLP+ launch
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India
  • Dr Reddys Laboratories Ltd consolidated Q3 FY2025-26 PAT drops to Rs. 1209.8 crores
  • Dr. Reddy's Laboratories announces Science-Based Net Zero Climate Targets
  • Immutep and Dr. Reddy's Enter Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
  • Dr. Reddy's receives European Commission Approval for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®
  • Dr Reddys Laboratories Ltd reports Rs. 1437.2 crores consolidated PAT in Q2FY26
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for AVT03 - denosumab
  • Dr. Reddy's launches novel molecule 'Tegoprazan' in India
  • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda®
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories
  • Dr. Reddy’s Laboratories Ltd Q3 FY2025 consolidated PAT higher at Rs. 1413.3 crores
  • Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
  • IPO-bound Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
  • Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025